Valneva announces upsized financing arrangement with leading us healthcare funds deerfield and orbimed

Saint - herblain (france), april 2 6 , 2022 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced an agreement to increase the principal amount of its existing $60 million debt financing agreement with funds managed by leading us-based healthcare investment firms deerfield management company and orbimed. this extension will provide valneva immediate access to $20 million, with an additional $20 million available upon potential conditional approval of its inactivated covid-19 vaccine candidate, vla2001, by the european medicines agency. the increased funding will be used to further invest in r&d, including market access preparations for valneva's chikungunya vaccine candidate, vla1553.
VALN Ratings Summary
VALN Quant Ranking